Furthermore, crenolanib has been studied in a small cohort of patients with R/R AML and FLT3-ITD or FLT3-TKD mutations who were not previously treated with any other FLT3 inhibitor. This evidence concerns the gene FLT3 and acute myeloid leukemia.